← Leaderboards

Mary McGrae McDermott

Northwestern University

Google Scholar ↗PubMed ↗ORCID ↗

$74,643,817

Attributed

$74,643,817

Total exposure

48

Grants

40

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $5.1M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$77,772,578 · 49

By mechanism

R01$58,430,322 · 21

UH3$7,609,778 · 6

R21$3,698,937 · 8

K12$2,491,116 · 1

M01$2,050,068 · 9

UG3$1,864,210 · 2

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Lower Extremity”

Michael A Province · Washington University$48,224,057
Thomas T Perls · Beth Israel Deaconess Medical Center$33,434,042
Bharat Thyagarajan · University Of Minnesota$30,553,972
S. Claiborne Johnston · University Of California San Francisco$21,675,687
Krista H Vandenborne · University Of Pennsylvania$21,082,899
Steven R Cummings · University Of California San Francisco$19,677,523

Research focus

Lower ExtremityPeripheral Arterial DiseaseFollow-UpParticipantWalkingRandomizedPerformancePreventMuscleFunctional DeclineImpairmentMediatingExerciseBiopsySkeletal MuscleMitochondriaQuality Of LifeFunctional DisabilityDensityPerfusionBlood CapillariesPhysical ActivityPrimary OutcomePersons

Grant awards (151)

IMProving mobility After revasCularizaTion in Peripheral Artery Disease: the IMPACT PAD Trial$1,432,256

UH3 · FY2025 · HL · contact PI

Response to Exercise and Nitric Oxide in PAD: the RESIST PAD Trial$644,095

R01 · FY2025 · AG · contact PI

Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD$639,982

R01 · FY2025 · AG · contact PI

COCOA flavanols to improve walking performance in PAD: the COCOA-PAD II Trial$620,290

R01 · FY2025 · AG · contact PI

BEET root juice to reverse functional impairment in PAD: The BEET PAD Trial$617,391

R01 · FY2025 · AG · contact PI

1/2 + PROmote weight loss in obese PAD patients to preVEnt mobility loss: the PROVE Trial$440,373

UH3 · FY2025 · HL · contact PI

ConProject-002$215,776

UH3 · FY2025 · HL · contact PI

ConProject-006$135,429

UH3 · FY2025 · HL · contact PI

ConProject-001$73,663

UH3 · FY2025 · HL · contact PI

ConProject-004$15,505

UH3 · FY2025 · HL · contact PI

IMProving mobility After revasCularizaTion in Peripheral Artery Disease: the IMPACT PAD Trial$1,264,646

UG3 · FY2024 · HL · contact PI

Response to Exercise and Nitric Oxide in PAD: the RESIST PAD Trial$682,982

R01 · FY2024 · AG · contact PI

Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD$659,870

R01 · FY2024 · AG · contact PI

BEET root juice to reverse functional impairment in PAD: The BEET PAD Trial$642,744

R01 · FY2024 · AG · contact PI

COCOA flavanols to improve walking performance in PAD: the COCOA-PAD II Trial$637,167

R01 · FY2024 · AG · contact PI

Far Red Light to Improve Functioning in PAD: the LIGHT PAD Trial$207,772

R21 · FY2024 · AG · contact PI

ENhancing exercise with LIGHT to improve functioning in PAD: the ENLIGHTEN PAD Trial$207,692

R21 · FY2024 · AG · contact PI

Pilot/Exploratory Studies Core (PESC)$160,780

P30 · FY2024 · AG · contact PI

Response to Exercise and Nitric Oxide in PAD: the RESIST PAD Trial$749,191

R01 · FY2023 · AG · contact PI

1/2 + PROmote weight loss in obese PAD patients to preVEnt mobility loss: the PROVE Trial$730,117

UH3 · FY2023 · HL · contact PI

Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD$671,581

R01 · FY2023 · AG · contact PI

BEET root juice to reverse functional impairment in PAD: The BEET PAD Trial$656,986

R01 · FY2023 · AG · contact PI

COCOA flavanols to improve walking performance in PAD: the COCOA-PAD II Trial$583,701

R01 · FY2023 · AG · contact PI

ConProject-002$307,883

UH3 · FY2023 · HL · contact PI

Pilot/Exploratory Studies Core (PESC)$295,205

P30 · FY2023 · AG · contact PI

ConProject-006$293,244

UH3 · FY2023 · HL · contact PI

Far Red Light to Improve Functioning in PAD: the LIGHT PAD Trial$267,564

R21 · FY2023 · AG · contact PI

ENhancing exercise with LIGHT to improve functioning in PAD: the ENLIGHTEN PAD Trial$267,489

R21 · FY2023 · AG · contact PI

FIsetin to Reduce Senescence and mobility impairmenT in PAD: the FIRST Pilot Randomized Trial$232,505

R21 · FY2023 · AG · contact PI

ConProject-001$33,577

UH3 · FY2023 · HL · contact PI

ConProject-004$15,413

UH3 · FY2023 · HL · contact PI

BEET root juice to reverse functional impairment in PAD: The BEET PAD Trial$739,760

R01 · FY2022 · AG · contact PI

Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD$723,137

R01 · FY2022 · AG · contact PI

1/2 + PROmote weight loss in obese PAD patients to preVEnt mobility loss: the PROVE Trial$651,671

UH3 · FY2022 · HL · contact PI

COCOA flavanols to improve walking performance in PAD: the COCOA-PAD II Trial$634,522

R01 · FY2022 · AG · contact PI

INTERmittent pneumatic ComprEssion for Disability rEversal in PAD: the INTERCEDE Trial$607,984

R01 · FY2022 · AG · contact PI

Pilot/Exploratory Studies Core (PESC)$444,629

P30 · FY2022 · AG · contact PI

ConProject-002$317,315

UH3 · FY2022 · HL · contact PI

ConProject-006$286,481

UH3 · FY2022 · HL · contact PI

FIsetin to Reduce Senescence and mobility impairmenT in PAD: the FIRST Pilot Randomized Trial$222,548

R21 · FY2022 · AG · contact PI

COCOA PAD II Trial: Microbiome Ancillary Study$182,955

R01 · FY2022 · AG · contact PI

ConProject-001$32,826

UH3 · FY2022 · HL · contact PI

ConProject-004$15,049

UH3 · FY2022 · HL · contact PI

COCOA flavanols to improve walking performance in PAD: the COCOA-PAD II Trial$708,737

R01 · FY2021 · AG · contact PI

Improve PAD PERformance with METformin. The PERMET Trial$698,232

R01 · FY2021 · HL · contact PI

1/2 + PROmote weight loss in obese PAD patients to preVEnt mobility loss: the PROVE Trial$663,980

UH3 · FY2021 · HL · contact PI

INTERmittent pneumatic ComprEssion for Disability rEversal in PAD: the INTERCEDE Trial$608,410

R01 · FY2021 · AG · contact PI

Pilot/Exploratory Studies Core (PESC)$431,680

P30 · FY2021 · AG · contact PI

ConProject-002$320,086

UH3 · FY2021 · HL · contact PI

ConProject-006$288,973

UH3 · FY2021 · HL · contact PI

APelin, EXercise, and mobility in Peripheral Artery Disease, the APEX-PAD Study$138,757

R21 · FY2021 · AG · contact PI

ConProject-001$39,746

UH3 · FY2021 · HL · contact PI

ConProject-004$15,175

UH3 · FY2021 · HL · contact PI

Improve PAD PERformance with METformin. The PERMET Trial$711,015

R01 · FY2020 · HL · contact PI

1/2 + PROmote weight loss in obese PAD patients to preVEnt mobility loss: the PROVE Trial$642,620

UH3 · FY2020 · HL · contact PI

INTERmittent pneumatic ComprEssion for Disability rEversal in PAD: the INTERCEDE Trial$637,156

R01 · FY2020 · AG · contact PI

ConProject-002$302,126

UH3 · FY2020 · HL · contact PI

Pilot/Exploratory Studies Core (PESC)$295,853

P30 · FY2020 · AG · contact PI

ConProject-006$285,337

UH3 · FY2020 · HL · contact PI

Unacylated Ghrelin to Improve FuncTioning in PAD: the GIFT Trial$202,189

R21 · FY2020 · AG · contact PI

APelin, EXercise, and mobility in Peripheral Artery Disease, the APEX-PAD Study$160,711

R21 · FY2020 · AG · contact PI

ConProject-001$39,943

UH3 · FY2020 · HL · contact PI

ConProject-004$15,214

UH3 · FY2020 · HL · contact PI

Improve PAD PERformance with METformin. The PERMET Trial$729,244

R01 · FY2019 · HL · contact PI

TELmisartan plus EXercise to improve functioning in PAD: The TELEX Trial$713,702

R01 · FY2019 · HL · contact PI

INTERmittent pneumatic ComprEssion for Disability rEversal in PAD: the INTERCEDE Trial$648,869

R01 · FY2019 · AG · contact PI

1/2 + PROmote weight loss in obese PAD patients to preVEnt mobility loss: the PROVE Trial$599,564

UG3 · FY2019 · HL · contact PI

Unacylated Ghrelin to Improve FuncTioning in PAD: the GIFT Trial$255,191

R21 · FY2019 · AG · contact PI

Improve PAD PERformance with METformin. The PERMET Trial$743,546

R01 · FY2018 · HL · contact PI

TELmisartan plus EXercise to improve functioning in PAD: The TELEX Trial$733,383

R01 · FY2018 · HL · contact PI

Low InTensity Exercise Intervention for Peripheral Artery Disease: The LITE Trial$712,501

R01 · FY2018 · HL · contact PI

INTERmittent pneumatic ComprEssion for Disability rEversal in PAD: the INTERCEDE Trial$672,485

R01 · FY2018 · AG · contact PI

Hepatocyte growth factor to Improve Functioning in PAD: the HI-PAD Study$172,008

R21 · FY2018 · AG · contact PI

Improve PAD PERformance with METformin. The PERMET Trial$812,566

R01 · FY2017 · HL · contact PI

TELmisartan plus EXercise to improve functioning in PAD: The TELEX Trial$746,212

R01 · FY2017 · HL · contact PI

Low InTensity Exercise Intervention for Peripheral Artery Disease: The LITE Trial$737,051

R01 · FY2017 · HL · contact PI

COCOA to improve walking performance in Peripheral Artery Disease: the COCOA-PAD Study$234,462

R21 · FY2017 · AG · contact PI

Hepatocyte growth factor to Improve Functioning in PAD: the HI-PAD Study$216,401

R21 · FY2017 · AG · contact PI

Supplement to Epicatechin-rich COCOA to improve walking performance in PAD: the COCOA-PAD-S Study$165,073

R21 · FY2017 · AG · contact PI

Low InTensity Exercise Intervention for Peripheral Artery Disease: The LITE Trial$759,140

R01 · FY2016 · HL · contact PI

TELmisartan plus EXercise to improve functioning in PAD: The TELEX Trial$748,491

R01 · FY2016 · HL · contact PI

COCOA to improve walking performance in Peripheral Artery Disease: the COCOA-PAD Study$215,843

R21 · FY2016 · AG · contact PI

PROgenitor Cell Release Plus Exercise To Improve Functional Performance In PAD$955,818

R01 · FY2015 · HL · contact PI

TELmisartan plus EXercise to improve functioning in PAD: The TELEX Trial$796,682

R01 · FY2015 · HL · contact PI

Low InTensity Exercise intervention for peripheral artery disease: The LITE Trial$781,987

R01 · FY2015 · HL · contact PI

RESveratrol To Improve Outcomes in oldeR pEople with PAD (the RESTORE Trial)$253,606

R21 · FY2015 · AG · contact PI

Supplement to RESveratrol To Improve Outcomes in oldeR pEople with PAD (the RESTORE-S Trial)$30,810

R21 · FY2015 · AG · contact PI

PROgenitor Cell Release Plus Exercise To Improve Functional Performance In PAD$1,227,493

R01 · FY2014 · HL · contact PI

Femoral Plaque Composition, Oxidative Stress, and Coronary Events$561,800

R01 · FY2014 · HL · contact PI

RESveratrol To Improve Outcomes in oldeR pEople with PAD (the RESTORE Trial)$248,316

R21 · FY2014 · AG · contact PI

PROgenitor Cell Release Plus Exercise To Improve Functional Performance In PAD$1,255,803

R01 · FY2013 · HL · contact PI

Femoral Plaque Composition, Oxidative Stress, and Coronary Events$654,099

R01 · FY2013 · HL · contact PI

PROgenitor cell release Plus Exercise to improve functional performance in PAD$1,239,870

R01 · FY2012 · HL · contact PI

Femoral Plaque Composition, Oxidative Stress, and Coronary Events$730,733

R01 · FY2012 · HL · contact PI

Blood Markers of Vulnerability in High Risk Vascular Patients$709,566

R01 · FY2012 · HL · contact PI

Vascular Medicine at Northwestern University$305,029

K12 · FY2012 · HL · contact PI

PROgenitor cell release Plus Exercise to improve functional performance in PAD$873,666

R01 · FY2011 · HL · contact PI

Femoral Plaque Composition, Oxidative Stress, and Coronary Events$790,308

R01 · FY2011 · HL · contact PI

Blood Markers of Vulnerability in High Risk Vascular Patients$709,640

R01 · FY2011 · HL · contact PI

Increasing Activity in Peripheral Arterial Disease$627,477

R01 · FY2011 · HL · contact PI

Vitamin D Levels and Peripheral Arterial Disease Outcomes$338,960

R01 · FY2011 · HL · contact PI

Blood Markers of Vulnerability in High Risk Vascular Patients$766,875

R01 · FY2010 · HL · contact PI

Increasing Activity in Peripheral Arterial Disease$732,744

R01 · FY2010 · HL · contact PI

Magnetic Resonance in Peripheral Arterial Disease$722,051

R01 · FY2010 · HL · contact PI

Vitamin D Levels and Peripheral Arterial Disease Outcomes$274,494

R01 · FY2010 · HL · contact PI

Reducing Risk Factors in Peripheral Arterial Disease$68,379

R01 · FY2010 · HL · contact PI

Vascular Medicine at Northwestern University$1,107,384

K12 · FY2009 · HL · contact PI

Blood Markers of Vulnerability in High Risk Vascular Patients$757,237

R01 · FY2009 · HL · contact PI

Increasing Activity in Peripheral Arterial Disease$754,949

R01 · FY2009 · HL · contact PI

Magnetic Resonance in Peripheral Arterial Disease$736,869

R01 · FY2009 · HL · contact PI

Increasing Activity in Peripheral Arterial Disease$754,757

R01 · FY2008 · HL · contact PI

Magnetic Resonance in Peripheral Arterial Disease$736,865

R01 · FY2008 · HL · contact PI

Reducing Risk Factors in Peripheral Arterial Disease$705,227

R01 · FY2008 · HL · contact PI

Vascular Medicine at Northwestern University$697,573

K12 · FY2008 · HL · contact PI

Inflammation and Peripheral Arterial Disease Outcomes$662,328

R01 · FY2008 · HL · contact PI

Improving Functioning in Peripheral Arterial Disease$947,146

R01 · FY2007 · HL · contact PI

Magnetic Resonance in Peripheral Arterial Disease$741,424

R01 · FY2007 · HL · contact PI

Reducing Risk Factors in Peripheral Arterial Disease$728,067

R01 · FY2007 · HL · contact PI

Inflammation and Peripheral Arterial Disease Outcomes$662,555

R01 · FY2007 · HL · contact PI

Vascular Medicine at Northwestern University$381,130

K12 · FY2007 · HL · contact PI

MECHANISMS OF DISABILITY IN PERIPHERAL ARTERIAL DISEASE (NHLBI R01-HL71223-01)$262,304

M01 · FY2007 · RR · contact PI

IMPROVING FUNCTIONING IN PERIPHERAL ARTERIAL DISEASE$196,500

M01 · FY2007 · RR · contact PI

REDUCING RISK FACTORS IN PERIPHERAL ARTERIAL DISEASE$91,852

M01 · FY2007 · RR · contact PI

Improving Functioning in Peripheral Arterial Disease$975,127

R01 · FY2006 · HL · contact PI

Reducing Risk Factors in Peripheral Arterial Disease$741,097

R01 · FY2006 · HL · contact PI

Inflammation and Peripheral Arterial Disease Outcomes$696,517

R01 · FY2006 · HL · contact PI

MECHANISMS OF DISABILITY IN PERIPHERAL ARTERIAL DISEASE (NHLBI R01-HL71223-01)$279,238

M01 · FY2006 · RR · contact PI

IMPROVING FUNCTIONING IN PERIPHERAL ARTERIAL DISEASE$214,978

M01 · FY2006 · RR · contact PI

Improving Functioning in Peripheral Arterial Disease$999,208

R01 · FY2005 · HL

Reducing Risk Factors in Peripheral Arterial Disease$768,706

R01 · FY2005 · HL

Mechanisms of Disability in Peripheral Arterial Disease$673,767

R01 · FY2005 · HL

Inflammation and Peripheral Arterial Disease Outcomes$646,255

R01 · FY2005 · HL

MECHANISMS OF DISABILITY IN PERIPHERAL ARTERIAL DISEASE (NHLBI R01-HL71223)$355,490

M01 · FY2005 · RR

IMPROVING FUNCTIONING IN PERIPHERAL ARTERIAL DISEASE$148,736

M01 · FY2005 · RR

Improving Functioning in Peripheral Arterial Disease$999,072

R01 · FY2004 · HL

Mechanisms of Disability in Peripheral Arterial Disease$675,882

R01 · FY2004 · HL

BLOOD FACTORS AND PERIPHERAL ARTERIAL DISEASE OUTCOMES$501,878

R01 · FY2004 · HL

Mechanisms of Disability in Peripheral Arterial Disease (NHLBI R01-HL71223-01)$422,284

M01 · FY2004 · RR

Peripheral Arterial Disease and Functional Outcomes$37,738

M01 · FY2004 · RR

Improving Functioning in Peripheral Arterial Disease$999,863

R01 · FY2003 · HL

Mechanisms of Disability in Peripheral Arterial Disease$664,576

R01 · FY2003 · HL

BLOOD FACTORS AND PERIPHERAL ARTERIAL DISEASE OUTCOMES$618,653

R01 · FY2003 · HL

Mechanisms of Disability in Peripheral Arterial Disease$644,697

R01 · FY2002 · HL

BLOOD FACTORS AND PERIPHERAL ARTERIAL DISEASE OUTCOMES$547,507

R01 · FY2002 · HL

BLOOD FACTORS AND PERIPHERAL ARTERIAL DISEASE OUTCOMES$431,734

R01 · FY2001 · HL

PERIPHERAL ARTERIAL DISEASE AND FUNCTIONAL OUTCOMES$385,912

R01 · FY2001 · HL

PERIPHERAL ARTERIAL DISEASE AND FUNCTIONAL OUTCOMES$0

M01 · FY2001 · RR

PERIPHERAL ARTERIAL DISEASE AND FUNCTIONAL OUTCOMES$360,550

R01 · FY2000 · HL

SECONDARY PREVENTION IN PERIHPERAL ARTERIAL DISEASE$278,374

R01 · FY2000 · HL

PERIPHERAL ARTERIAL DISEASE AND FUNCTIONAL OUTCOMES$20,474

M01 · FY2000 · RR

FUNCTIONAL STATUS &CARDIOVASCULAR OUTCOMES IN PERIPHERAL ARTERIAL DISEASE (PAD)$20,474

M01 · FY2000 · RR